Pr TAILLANDIER Luc

Automatic Extraction of PET RANO Criteria with an Externally Validated Deep Learning Model: Application to [18F]FDOPA PET Imaging.

Zaragori T, Rozenblum L, Rovera G, Stien G, Zinsz A, Taillandier L, Rudà R, Laurenge A, Morbelli S, Kas A, Verger A

Neuro Oncol. 2026 05 6;:

Amino acid PET imaging to monitor mIDH inhibitor treatments in patients with refractory IDH-mutant gliomas.

Stien G, Obara T, Truong M, Zaragori T, Blonski M, Taillandier L, Verger A

Eur J Nucl Med Mol Imaging. 2026 04 17;:

Prognostic Factors of IDH Wild-Type Glioblastoma After Extensive Surgery: A Multimodal Atlas of Tumor Locations, Recurrences and Management.

Selhane H, Obara T, Vogin G, Anxionnat R, Gauchotte G, Taillandier L, Blonski M, Rech F

Cancers (Basel). 2025 12 24;18(1):

From Compassionate Use Toward High-Level Evidence for Radiopharmaceutical Therapy in Recurrent Meningioma: The LUMEN-1 and MOMENTUM-1 Trials.

Tolboom N, Albert NL, Braat AJAT, Snijders TJ, Tabouret E, Taillandier L, Brendel M, Cecchin D, Aguiar-Fernandez P, Fraioli F, Guedj E, Traub-Weidinger T, Yakushev I, Van Weehaeghe D, Preusser M, Verger A

J Nucl Med. 2025 10 16;:

[Lu]Lu-DOTATATE for refractory meningiomas: factors associated with the therapeutic response and initial tumor dosimetric data.

Boursier C, Zaragori T, Garabedian N, Blonski M, Obara T, Taillandier L, Imbert L, Verger A

Eur J Nucl Med Mol Imaging. 2025 09 22;:

Automatic Segmentation of Primary Central Nervous System Lymphoma at Clinical Routine Postcontrast T1-weighted MRI.

Fu G, Nichelli L, Herrán de la Gala D, Loizillon S, Bousfiha C, Valabregue R, Alentorn A, Hoang-Xuan K, Mathon B, Soussain C, Marolleau JP, Paillassa J, Taillandier L, Agapé P, Schmitt A, Chinot O, Ahle G, Dormont D, Houillier C, Lehéricy S, Colliot O,

Radiol Imaging Cancer. 2025 09;7(5):e240446

PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): methodological application in [F]-FDOPA PET imaging.

Stien G, Zinsz A, Ahrari S, Taillandier L, Blonski M, Imbert L, Zaragori T, Verger A

EJNMMI Res. 2025 04 18;15(1):44

Pattern of recurrence after fractionated stereotactic reirradiation in adult glioblastoma.

Margulies A, Sahki N, Rech F, Vogin G, Blonski M, Peiffert D, Taillandier L, Lesanne G, Demogeot N

Radiat Oncol. 2025 02 28;20(1):28

Health-related quality of life in 62 patients with diffuse low-grade glioma during a non-therapeutic and progression-free phase: a cross-sectional study.

Obara T, Blonski M, Forest-Dodelin M, Rech F, Taillandier L

J Neurooncol. 2024 12 16;:

High-dose chemotherapy with autologous haematopoietic stem cell transplantation in patients with isolated vitreoretinal lymphoma: a LOC network study.

Mainguy A, Soussain C, Touitou V, Bennedjai A, Kodjikian L, Ghesquières H, Damaj G, Gressin R, Ducloyer JB, Chinot O, Vautier A, Moluçon-Chabrot C, Ahle G, Taillandier L, Marolleau JP, Chauchet A, Jardin F, Cassoux N, Malaise D, Toutée A, Touhami S, Le Garff-Tavernier M, Hoang-Xuan K, Choquet S, Houillier C

Bone Marrow Transplant. 2024 11 19;:

DTI analysis of the peritumoral zone of diffuse low-grade gliomas in progressing patients.

Chiche D, Taillandier L, Blonski M, Planel S, Obara T, Anxionnat R, Rech F

World Neurosurg. 2024 11 1;:

Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma.

Kacimi SEO, Dehais C, Feuvret L, Chinot O, Carpentier C, Bronnimann C, Vauleon E, Djelad A, Cohen-Jonathan Moyal E, Langlois O, Campone M, Ducloie M, Noel G, Cuzzubbo S, Taillandier L, Ramirez C, Younan N, Menei P, Dhermain F, Desenclos C, Ghiringhelli F, Bourg V, Ricard D, Faillot T, Appay R, Tabouret E, Nichelli L, Mathon B, Thomas A, Tran S, Bielle F, Alentorn A, Iorgulescu JB, Boëlle PY, Labreche K, Hoang-Xuan K, Sanson M, Idbaih A, Figarella-Branger D, Ducray F, Touat M,

J Clin Oncol. 2024 10 2;:JCO2400049

Descriptive epidemiology of 399 histologically confirmed newly diagnosed meningeal solitary fibrous tumours and haemangiopericytomas in France: 2006-2015.

Champeaux Depond C, Zouaoui S, Darlix A, Rigau V, Mathieu-Daudé H, Bauchet F, Khettab M, Trétarre B, Figarella-Branger D, Taillandier L, Boetto J, Pallud J, Peyre M, Lottin M, Bauchet L,

Acta Neurochir (Wien). 2024 08 2;166(1):320

Amino-acid PET as a prognostic tool after post Stupp protocol temozolomide therapy in high-grade glioma patients.

Zinsz A, Ahrari S, Becker J, Mortada A, Roch V, Doriat L, Santi M, Blonski M, Taillandier L, Zaragori T, Verger A

J Neurooncol. 2024 06 6;:

Descriptive epidemiology of 30,223 histopathologically confirmed meningiomas in France: 2006-2015.

Depond CC, Zouaoui S, Darlix A, Rigau V, Mathieu-Daudé H, Bauchet F, Khettab M, Trétarre B, Figarella-Branger D, Taillandier L, Boetto J, Pallud J, Zemmoura I, Roche PH, Bauchet L, ,,

Acta Neurochir (Wien). 2024 05 14;166(1):214

The role of [18 F]FDOPA PET as an adjunct to conventional MRI in the diagnosis of aggressive glial lesions.

Zinsz A, Pouget C, Rech F, Taillandier L, Blonski M, Amlal S, Imbert L, Zaragori T, Verger A

Eur J Nucl Med Mol Imaging. 2024 04 19;:

Semi-automated segmentation methods of SSTR PET for dosimetry prediction in refractory meningioma patients treated by SSTR-targeted peptide receptor radionuclide therapy.

Boursier C, Zaragori T, Bros M, Bordonne M, Melki S, Taillandier L, Blonski M, Roch V, Marie PY, Karcher G, Imbert L, Verger A

Eur Radiol. 2023 05 6;:

Added value of [F]FDOPA PET to the management of high-grade glioma patients after their initial treatment: a prospective multicentre study.

Darcourt J, Chardin D, Bourg V, Gal J, Schiappa R, Blonski M, Koulibaly PM, Almairac F, Mondot L, Le Jeune F, Collombier L, Kas A, Taillandier L, Verger A

Eur J Nucl Med Mol Imaging. 2023 04 22;:

Systemic relapses of primary CNS lymphomas (PCNSL): a LOC network study.

Dufour J, Choquet S, Hoang-Xuan K, Schmitt A, Ahle G, Houot R, Taillandier L, Gressin R, Casasnovas O, Marolleau JP, Tamburini J, Serrier C, Perez E, Paillassa J, Gyan E, Chauchet A, Ursu R, Kas A, Soussain C, Houillier C

Ann Hematol. 2023 03 29;:

Radiological evolution of progestogen-induced meningioma: A monocentric retrospective study.

Ahmed-Khalifa T, Gillet R, Blonski M, Rech F, Fresse A, Gillet P, Taillandier L, Petitpain N

Fundam Clin Pharmacol. 2023 01 24;:

Anti-Hu Antibodies in Patients With Neurologic Side Effects of Immune Checkpoint Inhibitors.

Farina A, Villagrán-García M, Ciano-Petersen NL, Vogrig A, Muñiz-Castrillo S, Taillandier L, Michaud M, Lefilliatre M, Wang A, Lepine Z, Picard G, Wucher V, Dhairi M, Fabien N, Goncalves D, Rogemond V, Joubert B, Honnorat J

Neurol Neuroimmunol Neuroinflamm. 2023 01;10(1):

Impact of fractionated stereotactic radiotherapy on activity of daily living and performance status in progressive/recurrent glioblastoma: a retrospective study.

Demogeot N, Salleron J, Rech F, Taillandier L, Royer P, Vogin G

Radiat Oncol. 2022 12 6;17(1):201

Molecular and clinical diversity in primary central nervous system lymphoma.

Hernández-Verdin I, Kirasic E, Wienand K, Mokhtari K, Eimer S, Loiseau H, Rousseau A, Paillassa J, Ahle G, Lerintiu F, Uro-Coste E, Oberic L, Figarella-Branger D, Chinot O, Gauchotte G, Taillandier L, Marolleau JP, Polivka M, Adam C, Ursu R, Schmitt A, Barillot N, Nichelli L, Lozano-Sánchez F, Ibañez-Juliá MJ, Peyre M, Mathon B, Abada Y, Charlotte F, Davi F, Stewart C, de Reyniès A, Choquet S, Soussain C, Houillier C, Chapuy B, Hoang-Xuan K, Alentorn A

Ann Oncol. 2022 11 16;:

Differentiating high-grade glioma progression from treatment-related changes with dynamic [F]FDOPA PET: a multicentric study.

Rozenblum L, Zaragori T, Tran S, Morales-Martinez A, Taillandier L, Blonski M, Rech F, Galanaud D, Kas A, Verger A

Eur Radiol. 2022 11 11;:

Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study.

Houillier C, Dureau S, Taillandier L, Houot R, Chinot O, Moluçon-Chabrot C, Schmitt A, Gressin R, Choquet S, Damaj G, Peyrade F, Abraham J, Delwail V, Gyan E, Sanhes L, Cornillon J, Garidi R, Delmer A, Al Jijakli A, Morel P, Waultier A, Paillassa J, Chauchet A, Gastinne T, Laadhari M, Plissonnier AS, Feuvret L, Cassoux N, Touitou V, Ricard D, Hoang-Xuan K, Soussain C

J Clin Oncol. 2022 07 14;:JCO2200491

Isolated intraocular relapses of primary cerebral lymphomas: AN LOC NETWORK STUDY.

Younan N, Soussain C, Choquet S, Cassoux N, Touitou V, Schmitt A, Chinot O, Oberic L, Damaj G, Houot R, Ghesquières H, Laribi K, Ahle G, Taillandier L, Paillassa J, Gyan E, Jardin F, Delwail V, Marolleau JP, Tempescul A, Agapé P, Bourniquel M, Vacheret F, Jdid I, Le Garff-Tavernier M, Malaise D, Alentorn A, Xuan KH, Houillier C

Hematol Oncol. 2022 07 5;:

Characteristics of Anaplastic Oligodendrogliomas Short-Term Survivors: A POLA Network Study.

Garnier L, Vidal C, Chinot O, Cohen-Jonathan Moyal E, Djelad A, Bronnimann C, Bekaert L, Taillandier L, Frenel JS, Langlois O, Colin P, Menei P, Dhermain F, Carpentier C, Gerazime A, Curtit E, Figarella-Branger D, Dehais C, Ducray F

Oncologist. 2022 May 6;27(5):414-423

Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network.

Schenone L, Houillier C, Tanguy ML, Choquet S, Agbetiafa K, Ghesquières H, Damaj G, Schmitt A, Bouabdallah K, Ahle G, Gressin R, Cornillon J, Houot R, Marolleau JP, Fornecker LM, Chinot O, Peyrade F, Bouabdallah R, Moluçon-Chabrot C, Gyan E, Chauchet A, Casasnovas O, Oberic L, Delwail V, Abraham J, Roland V, Waultier-Rascalou A, Willems L, Morschhauser F, Fabbro M, Ursu R, Thieblemont C, Jardin F, Tempescul A, Malaise D, Touitou V, Nichelli L, Le Garff-Tavernier M, Plessier A, Bourget P, Bonmati C, Wantz-Mézières S, Giordan Q, Dorvaux V, Charron C, Jabeur W, Hoang-Xuan K, Taillandier L, Soussain C,

Bone Marrow Transplant. 2022 Apr 14;:

Initial PCV Chemotherapy Followed by Radiotherapy Is Associated With a Prolonged Response But Late Neurotoxicity in 20 Diffuse Low-Grade Glioma Patients.

Blonski M, Obara T, Brzenczek C, Pouget C, Dillier C, Meyer M, Lavigne L, Forthoffer N, Broussois A, Gauchotte G, Baron MH, Rech F, Mézières S, Gaudeau Y, Verger A, Vogin G, Anxionnat R, Moureaux JM, Taillandier L

Front Oncol. 2022 ;12:827897

Molecular profile to guide personalized medicine in adult patients with primary brain tumors: results from the ProfiLER trial.

Bonneville-Levard A, Frappaz D, Tredan O, Lavergne E, Corset V, Agrapart V, Chabaud S, Pissaloux D, Wang Q, Attignon V, Cartalat S, Ducray F, Thomas-Maisonneuve L, Honnorat J, Meyronet D, Taillandier L, Blonski M, Viari A, Baudet C, Sohier E, Lantuejoul S, Paindavoine S, Treilleux I, Rodriguez C, Pérol D, Blay JY

Med Oncol. 2021 Nov 5;39(1):4

Effects of Carbidopa Premedication on F-FDOPA PET Imaging of Glioma: A Multiparametric Analysis.

Bros M, Zaragori T, Rech F, Blonski M, Hossu G, Taillandier L, Marie PY, Verger A

Cancers (Basel). 2021 Oct 24;13(21):

F-FDOPA PET for the non-invasive prediction of glioma molecular parameters: a radiomics study.

Zaragori T, Oster J, Roch V, Hossu G, Chawki MB, Grignon R, Pouget C, Gauchotte G, Rech F, Blonski M, Taillandier L, Imbert L, Verger A

J Nucl Med. 2021 May 20;:

TEMOBIC: Phase II Trial of Neoadjuvant Chemotherapy for Unresectable Anaplastic Gliomas: An ANOCEF Study.

Tabouret E, Fabbro M, Autran D, Hoang-Xuan K, Taillandier L, Ducray F, Barrie M, Sanson M, Kerr C, Cartalat-Carel S, Loundou A, Guillevin R, Mokhtari K, Figarella-Branger D, Delattre JY, Chinot O

Oncologist. 2021 Mar 30;:

Dynamic F-FDopa PET Imaging for Newly Diagnosed Gliomas: Is a Semiquantitative Model Sufficient?

Zaragori T, Doyen M, Rech F, Blonski M, Taillandier L, Imbert L, Verger A

Front Oncol. 2021 ;11:735257

What Does Quality of Care Mean in Lower-Grade Glioma Patients: A Precision Molecular-Based Management of the Tumor or an Individualized Medicine Centered on Patient's Choices?

Taillandier L, Obara T, Duffau H

Front Oncol. 2021 ;11:719014

Use of static and dynamic [F]-F-DOPA PET parameters for detecting patients with glioma recurrence or progression.

Zaragori T, Ginet M, Marie PY, Roch V, Grignon R, Gauchotte G, Rech F, Blonski M, Lamiral Z, Taillandier L, Imbert L, Verger A

EJNMMI Res. 2020 May 29;10(1):56

Management and outcome of primary CNS lymphoma in the modern era: An LOC network study.

Houillier C, Soussain C, Ghesquières H, Soubeyran P, Chinot O, Taillandier L, Lamy T, Choquet S, Ahle G, Damaj G, Agapé P, Moluçon-Chabrot C, Amiel A, Delwail V, Fabbro M, Jardin F, Chauchet A, Moles-Moreau MP, Morschhauser F, Casasnovas O, Gressin R, Fornecker LM, Abraham J, Marolleau JP, Tempescul A, Campello C, Colin P, Tamburini J, Laribi K, Serrier C, Haioun C, Chebrek S, Schmitt A, Blonski M, Houot R, Boyle E, Bay JO, Oberic L, Tabouret E, Waultier A, Martin-Duverneuil N, Touitou V, Cassoux N, Kas A, Mokhtari K, Charlotte F, Alentorn A, Feuvret L, Le Garff-Tavernier M, Costopoulos M, Mathon B, Peyre M, Delgadillo D, Douzane H, Genet D, Aidaoui B, Hoang-Xuan K, Gyan E

Neurology. 2020 Jan 6;:

Adult Diffuse Low-Grade Gliomas: 35-Year Experience at the Nancy France Neurooncology Unit.

Obara T, Blonski M, Brzenczek C, Mézières S, Gaudeau Y, Pouget C, Gauchotte G, Verger A, Vogin G, Moureaux JM, Duffau H, Rech F, Taillandier L

Front Oncol. 2020 ;10:574679

Complementary and alternative medicine use in glioma patients in France.

Le Rhun E, Devos P, Bourg V, Darlix A, Lorgis V, Ahle G, Boone M, Taillandier L, Curtit E, Gras L, Lebrun Frenay C, Gramatzki D, Ramirez C, Simon N, Weller M

J. Neurooncol.. 2019 Oct 21;:

Ki-67 and MCM6 labelling indices are correlated with overall survival in anaplastic oligodendroglioma, IDH1-mutant and 1p/19q-codeleted: a multicenter study from the French POLA network.

Pouget C, Hergalant S, Lardenois E, Lacomme S, Houlgatte R, Carpentier C, Dehais C, Rech F, Taillandier L, Sanson M, Appay R, Colin C, Figarella-Branger D, Battaglia-Hsu SF, Gauchotte G,

Brain Pathol.. 2019 Sep 27;:

Integration of dynamic parameters in the analysis of F-FDopa PET imaging improves the prediction of molecular features of gliomas.

Ginet M, Zaragori T, Marie PY, Roch V, Gauchotte G, Rech F, Blonski M, Lamiral Z, Taillandier L, Imbert L, Verger A

Eur. J. Nucl. Med. Mol. Imaging. 2019 Sep 16;:

Molecular Profiling Reclassifies Adult Astroblastoma into Known and Clinically Distinct Tumor Entities with Frequent Mitogen-Activated Protein Kinase Pathway Alterations.

Boisseau W, Euskirchen P, Mokhtari K, Dehais C, Touat M, Hoang-Xuan K, Sanson M, Capelle L, Nouet A, Karachi C, Bielle F, Guégan J, Marie Y, Martin-Duverneuil N, Taillandier L, Rousseau A, Delattre JY, Idbaih A

Oncologist. 2019 Jul 25;:

Long-term survival in patients with recurrent glioblastoma treated with bevacizumab: a multicentric retrospective study.

Morisse MC, Etienne-Selloum N, Bello-Roufai D, Blonski M, Taillandier L, Lorgis V, Noël G, Ahle G, Durán-Peña A, Boone M, Chauffert B

J. Neurooncol.. 2019 Jul 19;:

Chemotherapy and diffuse low-grade gliomas: a survey within the European Low-Grade Glioma Network.

Darlix A, Mandonnet E, Freyschlag CF, Pinggera D, Forster MT, Voss M, Steinbach J, Loughrey C, Goodden J, Banna G, Di Blasi C, Foroglou N, Hottinger AF, Baron MH, Pallud J, Duffau H, Rutten GJ, Almairac F, Fontaine D, Taillandier L, Pessanha Viegas C, Albuquerque L, von Campe G, Urbanic-Purkart T, Blonski M

Neurooncol Pract. 2019 Jul;6(4):264-273

A genome-wide association study identifies susceptibility loci for primary central nervous system lymphoma at 6p25.3 and 3p22.1: a LOC network study.

Labreche K, Daniau M, Sud A, Law PJ, Royer-Perron L, Holroyd A, Broderick P, Went M, Benazra M, Ahle G, Soubeyran P, Taillandier L, Chinot OL, Casasnovas O, Bay JO, Jardin F, Oberic L, Fabbro M, Damaj G, Brion A, Mokhtari K, Philippe C, Sanson M, Houillier C, Soussain C, Hoang-Xuan K, Houlston RS, Alentorn A,

Neuro-oncology. 2019 May 17;:

[Use of the PELICAN software for the creation and export of standardized pathology reports in central nervous system tumors: Example of meningiomas].

Yguel C, Clauzon D, Lacomme S, Lomazzi S, Lardenois E, Pouget C, Taillandier L, Rech F, Rigau V, Vignaud JM, Bauchet L, Gauchotte G

Ann Pathol. 2019 Mar 7;:

Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study.

Houillier C, Taillandier L, Dureau S, Lamy T, Laadhari M, Chinot O, Moluçon-Chabrot C, Soubeyran P, Gressin R, Choquet S, Damaj G, Thyss A, Abraham J, Delwail V, Gyan E, Sanhes L, Cornillon J, Garidi R, Delmer A, Tanguy ML, Al Jijakli A, Morel P, Bourquard P, Moles MP, Chauchet A, Gastinne T, Constans JM, Langer A, Martin A, Moisson P, Lacomblez L, Martin-Duverneuil N, Delgadillo D, Turbiez I, Feuvret L, Cassoux N, Touitou V, Ricard D, Hoang-Xuan K, Soussain C, ,

J. Clin. Oncol.. 2019 Feb 20;:JCO1800306

[Development and deployment of a standardized pathology report in lung cancer, basing on a data management software: The PELICAN software].

Yguel C, Clauzon D, Lacomme S, Siat J, Lomazzi S, Lardenois E, Taillandier L, Vignaud JM, Gauchotte G

Ann Pathol. 2019 Feb 5;:

Association of patterns of care, prognostic factors, and use of radiotherapy-temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study.

Fabbro-Peray P, Zouaoui S, Darlix A, Fabbro M, Pallud J, Rigau V, Mathieu-Daude H, Bessaoud F, Bauchet F, Riondel A, Sorbets E, Charissoux M, Amelot A, Mandonnet E, Figarella-Branger D, Duffau H, Tretarre B, Taillandier L, Bauchet L

J. Neurooncol.. 2018 Dec 6;:

Extent of Resection and Residual Tumor Thresholds for Postoperative Total Seizure Freedom in Epileptic Adult Patients Harboring a Supratentorial Diffuse Low-Grade Glioma.

Still MEH, Roux A, Huberfeld G, Bauchet L, Baron MH, Fontaine D, Blonski M, Mandonnet E, Guillevin R, Guyotat J, Taillandier L, Capelle L, Duffau H, Pallud J

Neurosurgery. 2018 Nov 5;:

Data-driven predictive models of diffuse low-grade gliomas under chemotherapy.

Ben Abdallah M, Blonski M, Wantz-Mezieres S, Gaudeau Y, Taillandier L, Moureaux JM, Darlix A, Menjot de Champfleur N, Duffau H

IEEE J Biomed Health Inform. 2018 May 7;:

A high F-FDOPA uptake is associated with a slow growth rate in diffuse Grade II-III gliomas.

Isal S, Gauchotte G, Rech F, Blonski M, Planel S, Chawki MB, Karcher G, Marie PY, Taillandier L, Verger A

Br J Radiol. 2018 Apr;91(1084):20170803

Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG).

Reyes-Botero G, Cartalat-Carel S, Chinot OL, Barrie M, Taillandier L, Beauchesne P, Catry-Thomas I, Barrière J, Guillamo JS, Fabbro M, Frappaz D, Benouaich-Amiel A, Le Rhun E, Campello C, Tennevet I, Ghiringhelli F, Tanguy ML, Mokhtari K, Honnorat J, Delattre JY

Oncologist. 2018 Feb 22;:

Relevance of two manual tumour volume estimation methods for diffuse low-grade gliomas.

Ben Abdallah M, Blonski M, Wantz-Mézières S, Gaudeau Y, Taillandier L, Moureaux JM

Healthc Technol Lett. 2018 Feb;5(1):13-17

Survey on current practice within the European Low-Grade Glioma Network: where do we stand and what is the next step?

Mandonnet E, Wager M, Almairac F, Baron MH, Blonski M, Freyschlag CF, Barone F, Fontaine D, Pallud J, Hegi M, Viegas C, Zetterling M, Spena G, Goodden J, Rutten GJ, Taillandier L, Foroglu N, Darlix A, Skrap M, Martino J, von Campe G, Madadaki C, Gayat E, de Witt Hamer P, Gil Robles S, Sarubbo S, Santorius T, Bello L, Forster MT, Duffau H

Neurooncol Pract. 2017 Dec;4(4):241-247

[Proposal of screening for diffuse low-grade gliomas in the population from 20 to 40years].

Mandonnet E, Taillandier L, Duffau H

Presse Med. 2017 Sep;:

[Hypofractionated stereotactic radiotherapy for brain metastasis: Benefit of additional whole brain radiotherapy?]

Royer P, Salleron J, Vogin G, Taillandier L, Clément-Duchêne C, Klein O, Faivre JC, Peiffert D, Bernier V

Cancer Radiother. 2017 Jul;:

Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas.

Lasolle H, Cortet C, Castinetti F, Cloix L, Caron P, Delemer B, Desailloud R, Jublanc C, Lebrun-Frenay C, Sadoul JL, Taillandier L, Batisse-Lignier M, Bonnet F, Bourcigaux N, Bresson D, Chabre O, Chanson P, Garcia C, Haissaguerre M, Reznik Y, Borot S, Villa C, Vasiljevic A, Gaillard S, Jouanneau E, Assié G, Raverot G

Eur. J. Endocrinol.. 2017 Jun;176(6):769-777

[Recommendations for the organ donation from patients with brain or medullary primitive tumors on behalf of the Association of the Neuro-oncologists of French Expression (ANOCEF) and the Club of Neuro-oncology of the French Society of Neurosurgery].

Frappaz D, Le Rhun E, Dagain A, Averland B, Bauchet L, Faure A, Guillaume C, Zouaoui S, Provot F, Vachiery F, Taillandier L, Hoang-Xuan K

Bull Cancer. 2017 May;:

Interactions between glioma and pregnancy: insight from a 52-case multicenter series.

Peeters S, Pagès M, Gauchotte G, Miquel C, Cartalat-Carel S, Guillamo JS, Capelle L, Delattre JY, Beauchesne P, Debouverie M, Fontaine D, Jouanneau E, Stecken J, Menei P, De Witte O, Colin P, Frappaz D, Lesimple T, Bauchet L, Lopes M, Bozec L, Moyal E, Deroulers C, Varlet P, Zanello M, Chretien F, Oppenheim C, Duffau H, Taillandier L, Pallud J,

J. Neurosurg.. 2017 Mar;:1-11

Epidemiology for primary brain tumors: a nationwide population-based study.

Darlix A, Zouaoui S, Rigau V, Bessaoud F, Figarella-Branger D, Mathieu-Daudé H, Trétarre B, Bauchet F, Duffau H, Taillandier L, Bauchet L

J. Neurooncol.. 2017 Feb;131(3):525-546

Temozolomide and Bevacizumab Induction before Chemoradiotherapy in Patients with Bulky Glioblastoma and/or with Severe Neurological Impairment.

Darmon I, Morisse MC, Coutte A, Blonski M, Rhun EL, Taillandier L, Roufai DB, Desenclos C, Trudel S, Faivre JC, Blanchard N, Chauffert B, Boone M

J Cancer. 2017 ;8(8):1417-1424

The etiopathogenesis of diffuse low-grade gliomas.

Darlix A, Gozé C, Rigau V, Bauchet L, Taillandier L, Duffau H

Crit. Rev. Oncol. Hematol.. 2017 Jan;109:51-62

Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial.

Tabouret E, Houillier C, Martin-Duverneuil N, Blonski M, Soussain C, Ghesquières H, Houot R, Larrieu D, Soubeyran P, Gressin R, Gyan E, Chinot O, Taillandier L, Choquet S, Alentorn A, Leclercq D, Omuro A, Tanguy ML, Hoang-Xuan K

Neuro-oncology. 2016 Dec;:

Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network.

Langner-Lemercier S, Houillier C, Soussain C, Ghesquières H, Chinot O, Taillandier L, Soubeyran P, Lamy T, Morschhauser F, Benouaich-Amiel A, Ahle G, Moles-Moreau MP, Moluçon-Chabrot C, Bourquard P, Damaj G, Jardin F, Larrieu D, Gyan E, Gressin R, Jaccard A, Choquet S, Brion A, Casasnovas O, Colin P, Reman O, Tempescul A, Marolleau JP, Fabbro M, Naudet F, Hoang-Xuan K, Houot R

Neuro-oncology. 2016 Sep;18(9):1297-303

Predictive models for diffuse low-grade glioma patients under chemotherapy.

Ben Abdallah M, Blonski M, Wantz-Mezieres S, Gaudeau Y, Taillandier L, Moureaux JM

Conf Proc IEEE Eng Med Biol Soc. 2016 Aug;2016:4357-4360

Prognostic value of health-related quality of life for death risk stratification in patients with unresectable glioblastoma.

Paquette B, Vernerey D, Chauffert B, Dabakuyo S, Feuvret L, Taillandier L, Frappaz D, Taillia H, Schott R, Ducray F, Fabbro M, Tennevet I, Ghiringhelli F, Guillamo JS, Durando X, Castera D, Frenay M, Campello C, Dalban C, Skrzypski J, Chinot O, Anota A, Bonnetain F

Cancer Med. 2016 Aug;5(8):1753-64

Statistical evaluation of manual segmentation of a diffuse low-grade glioma MRI dataset.

Ben Abdallah M, Blonski M, Wantz-Mezieres S, Gaudeau Y, Taillandier L, Moureaux JM

Conf Proc IEEE Eng Med Biol Soc. 2016 Aug;2016:4403-4406

Incidental diffuse low-grade gliomas: from early detection to preventive neuro-oncological surgery.

Lima GL, Zanello M, Mandonnet E, Taillandier L, Pallud J, Duffau H

Neurosurg Rev. 2016 Jul;39(3):377-84

[Systemic therapies administration for adult patients in neuro-oncology: The standards of the Association of the neuro-oncologists of French expression (ANOCEF)].

Simon N, Vasseur M, Chauffert B, Taillandier L, Le Rhun E

Bull Cancer. 2016 Apr;103(4):400-1

A Probabilistic Atlas of Diffuse WHO Grade II Glioma Locations in the Brain.

Parisot S, Darlix A, Baumann C, Zouaoui S, Yordanova Y, Blonski M, Rigau V, Chemouny S, Taillandier L, Bauchet L, Duffau H, Paragios N

PLoS ONE. 2016 ;11(1):e0144200

Venous thrombosis in patients with high-grade glioma.

Taillibert S, Taillandier L, Le Rhun E

Curr Opin Oncol. 2015 Nov;27(6):516-21

CellSearch technology applied to the detection and quantification of tumor cells in CSF of patients with lung cancer leptomeningeal metastasis.

Tu Q, Wu X, Le Rhun E, Blonski M, Wittwer B, Taillandier L, De Carvalho Bittencourt M, Faure GC

Lung Cancer. 2015 Sep 14. pii: S0169-5002(15)30052-0

Correlation of SUV-Derived Indices With Tumoral Aggressiveness of Gliomas in Static 18F-FDOPA PET: Use in Clinical Practice.

Janvier L, Olivier P, Blonski M, Morel O, Vignaud JM, Karcher G, Taillandier L, Verger A

Clin Nucl Med. 2015 Jul 22.

Descriptive epidemiology of 13,038 newly diagnosed and histologically confirmed meningiomas in France: 2006-2010.

Zouaoui S, Darlix A, Rigau V, Mathieu-Daudé H, Bauchet F, Bessaoud F, Fabbro-Peray P, Trétarre B, Figarella-Branger D, Taillandier L, Loiseau H, Bauchet L, ,,,,

Neurochirurgie. 2015 Jun;:

Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial.

Omuro A, Chinot O, Taillandier L, Ghesquieres H, Soussain C, Delwail V, Lamy T, Gressin R, Choquet S, Soubeyran P, Huchet A, Benouaich-Amiel A, Lebouvier-Sadot S, Gyan E, Touitou V, Barrié M, del Rio MS, Gonzalez-Aguilar A, Houillier C, Delgadillo D, Lacomblez L, Tanguy ML, Hoang-Xuan K

Lancet Haematol. 2015 Jun;2(6):e251-9

Isolated tumefactive demyelinating lesions: diagnosis and long-term evolution of 16 patients in a multicentric study.

Siri A, Carra-Dalliere C, Ayrignac X, Pelletier J, Audoin B, Pittion-Vouyovitch S, Debouverie M, Lionnet C, Viala F, Sablot D, Brassat D, Ouallet JC, Ruet A, Brochet B, Taillandier L, Bauchet L, Derache N, Defer G, Cabre P, de Seze J, Lebrun Frenay C, Cohen M, Labauge P

J Neurol. 2015 May 1.

New concepts in the management of diffuse low-grade glioma: Proposal of a multistage and individualized therapeutic approach.

Duffau H, Taillandier L

Neuro-oncology. 2015 Mar;17(3):332-42

[Supportive care, cognition and quality of life in brain metastases].

Le Rhun É, Taillibert S, Blonski M, Jouniaux Delbez N, Delgadillo D, Taillia H, Auquier P, Belin C, Bonnetain F, Varin D, Tallet A, Taillandier L

Cancer Radiother. 2015 Feb;19(1):55-60

Significant heterogeneity in the geographical distribution of diffuse grade II/III gliomas in France.

Darlix A, Zouaoui S, Virion JM, Rigau V, Mathieu-Daudé H, Blonski M, Reyes-Botero G, Bessaoud F, Trétarre B, Bauchet F, Capelle L, Fabbro M, Kerr C, Figarella-Branger D, Duffau H, Taillandier L, Bauchet L

J. Neurooncol.. 2014 Dec;120(3):547-55

[In Process Citation].

Bauchet L, Zouaoui S, Darlix A, Menjot de Champfleur N, Ferreira E, Fabbro M, Kerr C, Taillandier L

Neurochirurgie. 2014 Dec;60(6):352

A nonradiated grade II glioma that underwent delayed malignant transformation to a gliosarcoma with meningeal growth and dissemination.

Rech F, Rigau V, Fabbro M, Kerr C, Gauchotte G, Taillandier L, Duffau H

J Neurol Surg A Cent Eur Neurosurg. 2014 Nov;75(6):485-90

Assessment and treatment relevance in elderly glioblastoma patients.

Bauchet L, Zouaoui S, Darlix A, Menjot de Champfleur N, Ferreira E, Fabbro M, Kerr C, Taillandier L

Neuro-oncology. 2014 Nov;16(11):1459-68

Lack of GOPC-ROS1 (FIG-ROS1) rearrangement in adult human gliomas.

Karayan-Tapon L, Cortes U, Rivet P, Jermidi C, Vassal G, Wager M, Taillandier L

Eur. J. Cancer. 2014 Sep;50(13):2364-6

Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for diffuse low-grade gliomas.

Gozé C, Blonski M, Le Maistre G, Bauchet L, Dezamis E, Page P, Varlet P, Capelle L, Devaux B, Taillandier L, Duffau H, Pallud J

Neuro-oncology. 2014 Aug;16(8):1100-9

Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEFdagger.

Chauffert B, Feuvret L, Bonnetain F, Taillandier L, Frappaz D, Taillia H, Schott R, Honnorat J, Fabbro M, Tennevet I, Ghiringhelli F, Guillamo JS, Durando X, Castera D, Frenay M, Campello C, Dalban C, Skrzypski J, Chinot O

Ann Oncol. 2014 Jul;25(7):1442-7

Epileptic seizures in diffuse low-grade gliomas in adults.

Pallud J, Audureau E, Blonski M, Sanai N, Bauchet L, Fontaine D, Mandonnet E, Dezamis E, Psimaras D, Guyotat J, Peruzzi P, Page P, Gal B, Parraga E, Baron MH, Vlaicu M, Guillevin R, Devaux B, Duffau H, Taillandier L, Capelle L, Huberfeld G

Brain. 2014 Feb;137(Pt 2):449-62

Prolonged administration of adjuvant temozolomide improves survival in adult patients with glioblastoma.

Darlix A, Baumann C, Lorgis V, Ghiringhelli F, Blonski M, Chauffert B, Zouaoui S, Pinelli C, Rech F, Beauchesne P, Taillandier L

Anticancer Res. 2013 Aug;33(8):3467-74.

Neoadjuvant chemotherapy may optimize the extent of resection of World Health Organization grade II gliomas: a case series of 17 patients.

Blonski M, Pallud J, Goze C, Mandonnet E, Rigau V, Bauchet L, Fabbro M, Beauchesne P, Baron MH, Fontaine D, Peruzzi P, Darlix A, Duffau H, Taillandier L

J Neurooncol. 2013 Jun;113(2):267-75

Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization Grade II gliomas: a series of 1097 cases: clinical article.

Capelle L, Fontaine D, Mandonnet E, Taillandier L, Golmard JL, Bauchet L, Pallud J, Peruzzi P, Baron MH, Kujas M, Guyotat J, Guillevin R, Frenay M, Taillibert S, Colin P, Rigau V, Vandenbos F, Pinelli C, Duffau H

J Neurosurg. 2013 Jun;118(6):1157-68

Velocity of tumor spontaneous expansion predicts long-term outcomes for diffuse low-grade gliomas.

Pallud J, Blonski M, Mandonnet E, Audureau E, Fontaine D, Sanai N, Bauchet L, Peruzzi P, Frenay M, Colin P, Guillevin R, Bernier V, Baron MH, Guyotat J, Duffau H, Taillandier L, Capelle L

Neuro Oncol. 2013 May;15(5):595-606

Synergistic antitumor effect between gefitinib and fractionated irradiation in anaplastic oligodendrogliomas cannot be predicted by the Egfr signaling activity.

Pinel S, Mriouah J, Vandamme M, Chateau A, Plenat F, Guerin E, Taillandier L, Bernier-Chastagner V, Merlin JL, Chastagner P

PLoS One. 2013 Jul 18;8(7):e68333

Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases.

Soussain C, Choquet S, Fourme E, Delgadillo D, Bouabdallah K, Ghesquieres H, Damaj G, Dupriez B, Vargaftig J, Gonzalez A, Houillier C, Taillandier L, Hoang-Xuan K, Leblond V

Haematologica. 2012 Nov;97(11):1751-6

Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older.

Scott JG, Bauchet L, Fraum TJ, Nayak L, Cooper AR, Chao ST, Suh JH, Vogelbaum MA, Peereboom DM, Zouaoui S, Mathieu-Daude H, Fabbro-Peray P, Rigau V, Taillandier L, Abrey LE, DeAngelis LM, Shih JH, Iwamoto FM

Cancer. 2012 Nov 15;118(22):5595-600

Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas.

Gonzalez-Aguilar A, Idbaih A, Boisselier B, Habbita N, Rossetto M, Laurenge A, Bruno A, Jouvet A, Polivka M, Adam C, Figarella-Branger D, Miquel C, Vital A, Ghesquieres H, Gressin R, Delwail V, Taillandier L, Chinot O, Soubeyran P, Gyan E, Choquet S, Houillier C, Soussain C, Tanguy ML, Marie Y, Mokhtari K, Hoang-Xuan K

Clin Cancer Res. 2012 Oct 1;18(19):5203-11

Quantitative morphological magnetic resonance imaging follow-up of low-grade glioma: a plea for systematic measurement of growth rates.

Pallud J, Taillandier L, Capelle L, Fontaine D, Peyre M, Ducray F, Duffau H, Mandonnet E

Neurosurgery. 2012 Sep;71(3):729-39; discussion 739-40.

Upfront Bevacizumab and Temozolomide or Fotemustine before Radiotherapy for Patients with Glioblastoma and Severe Neurological Impairment at Diagnosis.

Bihan C, Foscolo S, Boone M, Blonski M, Coutte A, Darlix A, Beauchesne P, Lefranc M, Lorgis V, Taillandier L, Chauffert B

Case Rep Oncol. 2012 Sep;5(3):530-6

Waiting times before initiation of radiotherapy might not affect outcomes for patients with glioblastoma: a French retrospective analysis of patients treated in the era of concomitant temozolomide and radiotherapy.

Noel G, Huchet A, Feuvret L, Maire JP, Verrelle P, Le Rhun E, Aumont M, Thillays F, Sunyach MP, Henzen C, Missohou F, de Crevoisier R, Bondiau PY, Collin P, Durando X, Truc G, Kerr C, Bernier V, Clavier JB, Atlani D, D'Hombres A, Vinchon-Petit S, Lagrange JL, Taillandier L

J Neurooncol. 2012 Aug;109(1):167-75

Relation between bevacizumab dose intensity and high-grade glioma survival: a retrospective study in two large cohorts.

Lorgis V, Maura G, Coppa G, Hassani K, Taillandier L, Chauffert B, Apetoh L, Ladoire S, Ghiringhelli F

J Neurooncol. 2012 Apr;107(2):351-8

Expression of minichromosome maintenance MCM6 protein in meningiomas is strongly correlated with histologic grade and clinical outcome.

Gauchotte G, Vigouroux C, Rech F, Battaglia-Hsu SF, Soudant M, Pinelli C, Civit T, Taillandier L, Vignaud JM, Bressenot A

Am J Surg Pathol. 2012 Feb;36(2):283-91.

Improving the time-machine: estimating date of birth of grade II gliomas.

Gerin C, Pallud J, Grammaticos B, Mandonnet E, Deroulers C, Varlet P, Capelle L, Taillandier L, Bauchet L, Duffau H, Badoual M

Cell Prolif. 2012 Feb;45(1):76-90

Combination of neoadjuvant chemotherapy followed by surgical resection as a new strategy for WHO grade II gliomas: a study of cognitive status and quality of life.

Blonski M, Taillandier L, Herbet G, Maldonado IL, Beauchesne P, Fabbro M, Campello C, Goze C, Rigau V, Moritz-Gasser S, Kerr C, Ruda R, Soffietti R, Bauchet L, Duffau H

J Neurooncol. 2012 Jan;106(2):353-66

Interest of (18)FDG PET/CT for etiological investigation of paraneoplastics syndromes.

Roux V, Olivier P, Taillandier L, Louis S, Sauvee M, Karcher G

. 2011 Dec;35(12):641-51.

French brain tumor database: 5-year histological results on 25 756 cases.

Rigau V, Zouaoui S, Mathieu-Daude H, Darlix A, Maran A, Tretarre B, Bessaoud F, Bauchet F, Attaoua R, Fabbro-Peray P, Fabbro M, Kerr C, Taillandier L, Duffau H, Figarella-Branger D, Costes V, Bauchet L

Brain Pathol. 2011 Nov;21(6):633-44

Supportive care in neurooncology.

Taillandier L, Blonski M, Darlix A, Hoang Xuan K, Taillibert S, Cartalat Carel S, Piollet I, Le Rhun E

Rev Neurol (Paris). 2011 Oct;167(10):762-72

Primary CNS lymphoma in patients younger than 60: can whole-brain radiotherapy be deferred?

Omuro A, Taillandier L, Chinot O, Sierra Del Rio M, Carnin C, Barrie M, Soussain C, Tanguy ML, Choquet S, Leblond V, Hoang-Xuan K

J Neurooncol. 2011 Aug;104(1):323-30

Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.

Gallego Perez-Larraya J, Ducray F, Chinot O, Catry-Thomas I, Taillandier L, Guillamo JS, Campello C, Monjour A, Cartalat-Carel S, Barrie M, Huchet A, Beauchesne P, Matta M, Mokhtari K, Tanguy ML, Honnorat J, Delattre JY

J Clin Oncol. 2011 Aug 1;29(22):3050-5

Mental confusion in cancer.

Brunet M, Dauchy S, Farsi F, Fiorini B, Foubert V, Kazes M, Montaut T, Perrin S, Reich M, Riou R, Taillandier L

. 2011 Jul;13(7):357-72.

Peri-ictal pseudoprogression in patients with brain tumor.

Rheims S, Ricard D, van den Bent M, Taillandier L, Bourg V, Desestret V, Cartalat-Carel S, Hermier M, Monjour A, Delattre JY, Sanson M, Honnorat J, Ducray F

Neuro Oncol. 2011 Jul;13(7):775-82.

[Medulloblastomas: review].

Taillandier L, Blonski M, Carrie C, Bernier V, Bonnetain F, Bourdeaut F, Thomas IC, Chastagner P, Dhermain F, Doz F, Frappaz D, Grill J, Guillevin R, Idbaih A, Jouvet A, Kerr C, Donadey FL, Padovani L, Pallud J, Sunyach MP

Rev Neurol (Paris). 2011 May;167(5):431-48

NF-1Score: a prediction score for internal neurofibromas in neurofibromatosis-1.

Sbidian E, Wolkenstein P, Valeyrie-Allanore L, Rodriguez D, Hadj-Rabia S, Ferkal S, Lacour JP, Leonard JC, Taillandier L, Sportich S, Berbis P, Bastuji-Garin S

J Invest Dermatol. 2010 Sep;130(9):2173-8

Up-front temozolomide in elderly patients with glioblastoma.

Laigle-Donadey F, Figarella-Branger D, Chinot O, Taillandier L, Cartalat-Carel S, Honnorat J, Kaloshi G, Delattre JY, Sanson M

J Neurooncol. 2010 Aug;99(1):89-94

Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004.

Bauchet L, Mathieu-Daude H, Fabbro-Peray P, Rigau V, Fabbro M, Chinot O, Pallusseau L, Carnin C, Laine K, Schlama A, Thiebaut A, Patru MC, Bauchet F, Lionnet M, Wager M, Faillot T, Taillandier L, Figarella-Branger D, Capelle L, Loiseau H, Frappaz D, Campello C, Kerr C, Duffau H, Reme-Saumon M, Tretarre B, Daures JP, Henin D, Labrousse F, Menei P, Honnorat J

Neuro Oncol. 2010 Jul;12(7):725-35

Interest and nature of the psychological care for patients and close relations in a medical dedicated neuro-oncology unit

Lanfroy R, Busch E, Colmar K, Bremond A, Garat E, Nicole A, Lanoix AS, Beauchesne P, Taillandier L

Psycho-oncologie. 2010 Jun;4(2):72-83

Prolonged survival for patients with newly diagnosed, inoperable glioblastoma with 3-times daily ultrafractionated radiation therapy.

Beauchesne P, Bernier V, Carnin C, Taillandier L, Djabri M, Martin L, Michel X, Maire JP, Khalil T, Kerr C, Gorlia T, Stupp R, Pedeux R

Neuro Oncol. 2010 Jun;12(6):595-602

Pregnancy increases the growth rates of World Health Organization grade II gliomas.

Pallud J, Mandonnet E, Deroulers C, Fontaine D, Badoual M, Capelle L, Guillet-May F, Page P, Peruzzi P, Jouanneau E, Frenay M, Cartalat-Carel S, Duffau H, Taillandier L

Ann Neurol. 2010 Mar;67(3):398-404.

Inter- and intrapatients comparison of WHO grade II glioma kinetics before and after surgical resection.

Mandonnet E, Pallud J, Fontaine D, Taillandier L, Bauchet L, Peruzzi P, Guyotat J, Bernier V, Baron MH, Duffau H, Capelle L

Neurosurg Rev. 2010 Jan;33(1):91-6

Influence of pregnancy in the behavior of diffuse gliomas: clinical cases of a French glioma study group.

Pallud J, Duffau H, Razak RA, Barbarino-Monnier P, Capelle L, Fontaine D, Frenay M, Guillet-May F, Mandonnet E, Taillandier L

J Neurol. 2009 Dec;256(12):2014-20

Epilepsy and insular Grade II gliomas: an interdisciplinary point of view from a retrospective monocentric series of 46 cases.

Taillandier L, Duffau H

Neurosurg Focus. 2009 Aug;27(2):E8.

Turcot syndrome: a case report

Sanou R, Anxionnat R, Taillandier L, Bigard MA, Regent D, Bracard S

J Radiol. 2009 Jul-Aug;90(7-8 Pt 1):842-4.

Concurrent radiotherapy: fotemustine combination for newly diagnosed malignant glioma patients, a phase II study.

Beauchesne PD, Taillandier L, Bernier V, Carnin C

Cancer Chemother Pharmacol. 2009 Jun;64(1):171-5

Re-operation is a safe and effective therapeutic strategy in recurrent WHO grade II gliomas within eloquent areas.

Martino J, Taillandier L, Moritz-Gasser S, Gatignol P, Duffau H

Acta Neurochir (Wien). 2009 May;151(5):427-36; discussion 436

[Prescription guidebook for temozolomide usage in brain tumors]

Tilleul P, Brignone M, Hassani Y, Taillandier L, Taillibert S, Cartalat-Carel S, Borget I, Chinot O

Bull Cancer. 2009 May;96(5):579-89.

Prognostic significance of imaging contrast enhancement for WHO grade II gliomas.

Pallud J, Capelle L, Taillandier L, Fontaine D, Mandonnet E, Guillevin R, Bauchet L, Peruzzi P, Laigle-Donadey F, Kujas M, Guyotat J, Baron MH, Mokhtari K, Duffau H

Neuro Oncol. 2009 Apr;11(2):176-82

[From the concept of care continuity to the necessary interdisciplinarianism in neuro-oncology]

Garat E, Duffau H, Taillandier L

Soins. 2009 Mar;(733):44-6.

Interest in association of bevacizumab/irinotecan in the treatment of glioblastoma. A multicentric study of ANOCEF

Guiu S, Taillibert S, Chinot O, Taillandier L, Honnorat J, Dietrich PY, Maire JP, Guillamo JS, Guiu B, Catry-Thomas I, Capelle F, Thiebaut A, Cartalat-Carel S, Deville C, Fumoleau P, Xuan KH, Chauffert B

Rev Neurol. 2009 Jan;165 Suppl. 1:S16-8

Interest of liposomal doxorubicin as a radiosensitizer in malignant glioma xenografts

Labussiere M, Aarnink A, Pinel S, Taillandier L, Escanye JM, Barberi-Heyob M, Bernier-Chastagner V, Plenat F, Chastagner P

Anticancer Drugs. 2008 Nov;19(10):991-8.

Intraoperative subcortical stimulation mapping of language pathways in a consecutive series of 115 patients with Grade II glioma in the left dominant hemisphere.

Duffau H, Peggy Gatignol ST, Mandonnet E, Capelle L, Taillandier L

J Neurosurg. 2008 Sep;109(3):461-71.

Computational modeling of the WHO grade II glioma dynamics: principles and applications to management paradigm.

Mandonnet E, Pallud J, Clatz O, Taillandier L, Konukoglu E, Duffau H, Capelle L

Neurosurg Rev. 2008 Jul;31(3):263-9

[Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study]

Guiu S, Taillibert S, Chinot O, Taillandier L, Honnorat J, Dietrich PY, Maire JP, Guillamo JS, Guiu B, Catry-Thomas I, Capelle F, Thiebaut A, Cartalat-Carel S, Deville C, Fumoleau P, Desjardins A, Xuan KH, Chauffert B

Rev Neurol (Paris). 2008 Jun-Jul;164(6-7):588-94

Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire.

Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, Casasnovas O, Dupriez B, Souleau B, Taksin AL, Gisselbrecht C, Jaccard A, Omuro A, Sanson M, Janvier M, Kolb B, Zini JM, Leblond V

J Clin Oncol. 2008 May 20;26(15):2512-8

Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly.

Omuro AM, Taillandier L, Chinot O, Carnin C, Barrie M, Hoang-Xuan K

J Neurooncol. 2007 Nov;85(2):207-11

Clinical follow-up of 304 patients with multiple sclerosis three years after mitoxantrone treatment.

Debouverie M, Taillandier L, Pittion-Vouyovitch S, Louis S, Vespignani H

Mult Scler. 2007 Jun;13(5):626-31

Radiotherapy for glioblastoma in the elderly

Keime-Guibert F, Chinot O, Taillandier L, Cartalat-Carel S, Frenay M, Kantor G, Guillamo J, Jadaud E, Colin P, Bondiau P, Menei P, Loiseau H, Bernier V, Honnorat J, Barrie M, Mokhtari K, Mazeron J, Bissery A, Delattre J, Lacomblez L, Levy-Soussan M, Mallet A, Houssard C, Delgadillo D, Poitou M, Hoang-Xuan K, Sanson M, Carpentier AF, Laigle-Donadey F, Taillibert S, Cornu P, Omuro A, Capelle L, Boch AL, Duffau H, Simon JM, Medioni J, Broet P, Schmitt A, Garat E, Mathieu P, Camille N, Collin JP, Bailet B, Ciais C, Fauchon F, Lebrun C, Guesdan G, Stadelmaier N, Lombard I, Delassus P, Lalevec C, Aubin G, Fournier D, Hayek G

N Engl J Med. 2007 Apr 12;356(15):1527-35.

Episodic nocturnal wandering in a patient with epilepsy due to a right temporoinsular low-grade glioma: relief following resection. Case report.

Duffau H, Kujas M, Taillandier L

J Neurosurg. 2006 Mar;104(3):436-9.

Atypical clinical presentation of intracranial hypotension: coma.

Kremer S, Taillandier L, Schmitt E, Bologna S, Moret C, Picard L, Bracard S

J Neurol. 2005 Nov;252(11):1399-400

Comparison of intravenous and intra-arterial urokinase thrombolysis for acute ischaemic stroke.

Ducrocq X, Bracard S, Taillandier L, Anxionnat R, Lacour JC, Guillemin F, Debouverie M, Bollaert PE

J Neuroradiol. 2005 Jan;32(1):26-32.

Fiche personne

Coordonnées

Territoire

Statut

Affiliation

Équipes/plateformes

Projets

Publications